Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Journey Medical (DERM) Income from Continuing Operations: 2020-2025

Historic Income from Continuing Operations for Journey Medical (DERM) over the last 5 years, with Sep 2025 value amounting to -$2.3 million.

  • Journey Medical's Income from Continuing Operations rose 3.14% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.5 million, marking a year-over-year increase of 53.41%. This contributed to the annual value of -$14.7 million for FY2024, which is 280.79% down from last year.
  • Journey Medical's Income from Continuing Operations amounted to -$2.3 million in Q3 2025, which was up 38.04% from -$3.7 million recorded in Q2 2025.
  • In the past 5 years, Journey Medical's Income from Continuing Operations registered a high of $16.8 million during Q3 2023, and its lowest value of -$21.8 million during Q4 2021.
  • For the 3-year period, Journey Medical's Income from Continuing Operations averaged around -$2.6 million, with its median value being -$3.4 million (2024).
  • As far as peak fluctuations go, Journey Medical's Income from Continuing Operations plummeted by 36,810.34% in 2021, and later soared by 266.56% in 2023.
  • Journey Medical's Income from Continuing Operations (Quarterly) stood at -$21.8 million in 2021, then spiked by 51.07% to -$10.6 million in 2022, then surged by 79.86% to -$2.1 million in 2023, then skyrocketed by 173.82% to $1.6 million in 2024, then grew by 3.14% to -$2.3 million in 2025.
  • Its Income from Continuing Operations was -$2.3 million in Q3 2025, compared to -$3.7 million in Q2 2025 and -$4.1 million in Q1 2025.